Accumulation of beta amyloid in the brain is a hallmark pathological feature of Alzheimer’s disease and the target for newly approved therapeutic interventions. While imaging and cerebrospinal fluid (CSF) biomarker testing can measure amyloid pathology, blood biomarkers are a noninvasive testing alternative.

In this test-specific episode of the "Answers From the Lab" podcast, Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new plasma biomarker assay, a highly accessible and accurate testing option for symptomatic individuals aged 50 and above.

"One of the challenges with the use of CSF biomarkers is the invasiveness of the CSF collection and also the access to have a lumbar puncture performed," says Dr. Algeciras-Schimnich. "The introduction of Alzheimer's disease blood biomarkers into clinical practice provides a noninvasive tool to aid in the evaluation of patients presenting with mild cognitive impairment as well as in determining the eligibility for these disease-modifying therapies."

Clinically validated through Mayo Clinic research, this immunoassay identifies phosphorylated Tau 217 (p-Tau217). The test interpretation cutpoints have been optimized to provide a sensitivity of 92% and specificity of 96% for the detection of abnormal amyloid pathology based on amyloid-PET positivity.

“Now that we have disease modifying therapies available, biomarker testing for Alzheimer's disease will become an essential component of the clinical evaluations of patients with cognitive impairment,” Dr. Algeciras-Schimnich says. “The plasma assay for p-Tau217 will allow us to provide a rapid and a scalable tool for the detection of amyloid pathology.”

Listen to learn more about Mayo Clinic Laboratories' plasma biomarker testing for Alzheimer’s disease.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PT217   | Phospho-Tau 217, Plasma

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less